每经AI快讯，8月21日，中证转债指数午盘上涨0.75%，报485.73点。其中，东时转债、水羊转债、大元 转债、赛龙转债、易瑞转债涨幅居前，分别涨20.00%、11.18%、9.89%、8.02%、7.47%。崇达转2、金 田转债、金轮转债、力诺转债、博瑞转债跌幅居前，分别跌6.55%、5.42%、4.50%、3.74%、3.38%。 （文章来源：每日经济新闻） ...

Group 1 - The stock price of Yirui Bio is reported at 13.15 yuan, down 2.01% from the previous trading day, with an intraday high of 13.46 yuan and a low of 12.96 yuan, and a trading volume of 114 million yuan [1] - Yirui Bio's main business includes food rapid testing, animal epidemic disease testing, and in vitro diagnostics, with food rapid testing accounting for over 90% of its business [1] - The company is associated with sectors such as chemical pharmaceuticals, smallpox virus prevention, and specialized and innovative enterprises [1] Group 2 - On August 20, Yirui Bio announced that the board decided not to redeem the "Yirui Convertible Bonds" early, and if redemption clauses are triggered again within the next three months, the company will still not exercise its redemption rights [1] - On the same day, the net inflow of main funds was 4.467 million yuan, while the cumulative net outflow of main funds over the past five days was 10.4952 million yuan [1]

Group 1 - The core viewpoint of the article highlights the significant financial performance of Muyuan Foods, reporting a net profit of 10.53 billion yuan in the first half of the year, representing a year-on-year increase of 1169.77% [1] - ST Zhongzhuang has received a court decision and appointed a restructuring manager, leading to the resumption of trading for its stocks and convertible bonds [1] - Several convertible bonds, including Yirui, Sailong, and Dongfeng, have announced that they will not be forcibly redeemed [1][2] Group 2 - The article provides a detailed table of convertible bonds, including their current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [4][6] - Specific convertible bonds such as Dayu, Puna, and Guanda are listed with their respective current prices and conversion values, indicating their market performance and potential investment opportunities [4][6]

Core Viewpoint - The China Convertible Bond Index opened lower by 0.01%, indicating a slight decline in the market sentiment towards convertible bonds [1] Group 1: Market Performance - Tianlu Convertible Bond and Surveying and Mapping Convertible Bond rose nearly 6%, showing strong performance among certain bonds [1] - Saili Convertible Bond increased by nearly 4%, reflecting positive investor interest [1] - Yirui Convertible Bond and Julong Convertible Bond both saw gains of over 3%, indicating a favorable trend [1] - Dayu Convertible Bond dropped by over 3%, suggesting some negative sentiment [1] - Xizi Convertible Bond, Liugong Convertible Bond, and Lidong Convertible Bond all fell by over 1%, highlighting a broader decline in certain bonds [1]

Core Viewpoint - The announcement details the planned share reduction by the controlling shareholder and actual controller of Yirui Biological, which is not expected to significantly impact the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd., the controlling shareholder, plans to reduce its holdings by up to 3,531,208 shares, representing 0.88% of the total share capital [1]. - The actual controller, Zhu Hai, intends to reduce his holdings by up to 7,521,390 shares, accounting for 1.87% of the total share capital [1]. - The total planned reduction by both parties does not exceed 3% of the company's total share capital, with specific limits on the number of shares that can be sold within a 90-day period [1]. Group 2: Company Background and Financials - Yirui Biological was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 9, 2021, with an initial issuance of 40.86 million shares at a price of 5.31 yuan per share, raising a total of 217 million yuan [2]. - The company has raised a total of 545 million yuan from two fundraising events, with the first round netting 175 million yuan after expenses [3][4]. - The net profit attributable to shareholders for the years 2021, 2022, 2023, and 2024 were 236.51 million yuan, 82.97 million yuan, -184.91 million yuan, and 17.12 million yuan, respectively [4][5]. Group 3: Financial Performance - In 2024, the company's operating revenue is projected to be 224.25 million yuan, a decrease of 11.75% from 2023 [5]. - The net profit attributable to shareholders is expected to increase by 109.26% in 2024, reaching 17.12 million yuan, compared to a loss of 184.91 million yuan in 2023 [5]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of 34.26 million yuan in 2024, compared to a negative cash flow of -37.25 million yuan in 2023, marking a 191.97% increase [5].

Core Viewpoint - The share reduction plan by major shareholders of Yirui Biological has been completed, resulting in a total cash-out of approximately 8.83 million yuan from the sales of shares [1][2]. Shareholder Reduction Summary - Yirui Biological's major shareholders, Yidari and Yikairei, executed their share reduction plans, with Yidari reducing 411,200 shares (0.1025% of total shares) and Yikairei reducing 575,700 shares (0.1435% of total shares) [1][3]. - Yidari's share reduction occurred through concentrated bidding and block trading, with an average price of 9.33 yuan per share for 116,200 shares and 8.76 yuan per share for 295,000 shares [3]. - Yikairei's share reduction also involved concentrated bidding and block trading, with an average price of 9.30 yuan per share for 275,700 shares and 8.66 yuan per share for 300,000 shares [3]. Shareholder Equity Changes - Shareholder Wang Tianyi reduced his holdings by 6,337,700 shares (1.5792% of total shares) from April 25 to June 6, 2025, bringing his total holdings down to 20,065,821 shares (4.999984% of total shares) [2][4]. - Wang Tianyi's reduction means he is no longer a major shareholder with over 5% ownership [2][4]. Company Financial Activities - Yirui Biological raised a total of 217 million yuan during its IPO, with a net amount of 175 million yuan after deducting issuance costs [6]. - The company issued convertible bonds worth 328.2 million yuan in August 2023, which began trading on September 6, 2023 [7].

Core Viewpoint - Shenzhen Yirui Biological Technology Co., Ltd. announced the resumption of conversion for its convertible bonds "Yirui Convertible Bonds" (bond code: 123220) after a temporary suspension due to the 2024 annual equity distribution [1][3]. Summary by Relevant Sections - **Convertible Bond Information** - The convertible bond "Yirui Convertible Bonds" will be suspended from conversion from May 20, 2025, to May 27, 2025, due to the implementation of the 2024 annual equity distribution [1][3]. - The resumption of conversion will take place on May 28, 2025, which is the first trading day after the equity distribution record date [1][3]. - **Bond Details** - Bond code: 123220 - Bond abbreviation: Yirui Convertible Bonds - Conversion period: February 26, 2024, to August 17, 2029 [3].

Core Viewpoint - Shenzhen Yirui Biological Technology Co., Ltd. announced the suspension of the conversion of its convertible bonds during the 2024 annual equity distribution period, which will take place from May 20, 2025, until the equity registration date for the distribution [1][2]. Group 1: Equity Distribution Announcement - The company held its 2024 annual shareholders' meeting on May 16, 2025, where it approved the profit distribution plan for the year [1]. - The equity distribution will be adjusted if there are changes in the company's share capital before the implementation of the profit distribution plan, maintaining the total distribution amount [1]. Group 2: Convertible Bond Conversion Suspension - According to regulations, the conversion of the "Yirui Convertible Bonds" will be suspended from May 20, 2025, until the equity registration date for the 2024 annual distribution [2]. - The bonds will resume conversion on the first trading day after the equity registration date [2]. Group 3: Adjustment of Conversion Price - The company will adjust the conversion price of the bonds based on specific formulas if there are changes in share capital, such as stock dividends, capital increases, or cash dividends [2][3]. - The adjustment formulas include various scenarios, ensuring that the conversion price reflects the changes in equity distribution accurately [2][3].

Core Viewpoint - The China Convertible Bond Index opened lower by 0.05%, indicating a slight decline in the market sentiment towards convertible bonds [1] Group 1: Market Performance - The price of the Puli Convertible Bond dropped significantly by 33.7%, reflecting a major sell-off in this specific bond [1] - The Feikai Convertible Bond fell by 5.9%, contributing to the overall negative trend in the market [1] - The Huaxiang Convertible Bond experienced a decline of nearly 3%, further indicating weakness in the sector [1] Group 2: Positive Performers - The Yunjiji Convertible Bond saw an increase of 9.8%, standing out as a strong performer amidst the overall market decline [1] - The Jingda Convertible Bond rose by 4%, showing resilience in its performance [1] - Other bonds such as Yirui Convertible Bond, Jiuzhou Convertible Bond, Jieneng Convertible Bond, and Hengfeng Convertible Bond all increased by 1.8%, indicating some positive movement in the market [1]